arrow
K

Kenneth I. Ataga

center for sickle cell disease
H指数:50
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Multicenter, Open-Label, Phase 2 Trial Comparing Crizanlizumab Combined With Standard Therapy to Standard Therapy Alone on Renal Function in Patients With Sickle Cell Nephropathy (STEADFAST)

一项多中心、开放标签、II期临床试验,比较克瑞扎尼鲁单抗联合标准疗法与单独标准疗法对镰状细胞肾病患者的肾功能影响(STEADFAST)

2026-07-280
OAAI
The Association between Urinary Biomarkers 3-Indoxyl Sulfate, Monocyte Chemoattractant Protein-1, Neutrophil Gelatinase-Associated Lipocalin and Klotho with Chronic Kidney Disease in Patients with Sickle Cell Disease

尿液中3-Indoxyl Sulfate、单核细胞趋化蛋白-1、中性粒细胞明胶酶相关脂质运载蛋白和Klotho生物标志物与镰状细胞病患者慢性肾脏疾病的关系

BLOOD
IF23.1
2024-11-050
PRE
Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1-2 trial
2024-05-011
PRE
Expert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA modified Delphi panel

接受crizanlizumab治疗的镰状细胞病 (SCD) 患者输注相关反应 (IRRs) 管理专家共识: RAND/UCLA改良Delphi小组

2024-04-201
PRE
; ); ); );
2021-05-0178
PRE